Alectinib (Alecensa) clinical trials

Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib In Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

This study compared two cancer drugs, Alecensa and XALKORI, for people with a specific type of advanced lung cancer (ALK-positive non-small cell lung cancer) who haven't had treatment before. Researchers wanted to see which drug worked better at stopping cancer growth and how patients felt.